Lymphoma

Lymphoma is a cancer of the lymphatic system that starts in white blood cells called lymphocytes. The two main groups are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), which includes many subtypes (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone/MALT, Burkitt). There is no routine population screening for lymphoma. Most cases come to light after symptoms develop or when routine labs or imaging look abnormal. Diagnosis and classification require a tissue biopsy plus specialized pathology, flow cytometry, and genetic tests. Lab tests also help assess organ function, track disease activity, and monitor treatment.

Ulta Lab Tests provides convenient access to supportive blood tests that clinicians use alongside biopsy and imaging to evaluate, stage, and monitor lymphoma.


Signs & Symptoms (When to consider testing)

  • Lymph nodes & spleen: painless, persistent lymph node swelling in the neck, armpit, or groin; feeling of fullness under the left ribs (enlarged spleen).

  • Systemic “B” symptoms: fevers, drenching night sweats, unintentional weight loss.

  • General: fatigue, itching, decreased appetite.

  • Local effects: cough or chest discomfort (mediastinal nodes), abdominal pain or bloating, persistent tonsil enlargement.

  • Lab clues: unexplained anemia, high LDH, abnormal white counts, or elevated inflammatory markers.

Urgent care is advised for rapidly enlarging nodes, severe shortness of breath, or signs of spinal cord compression.


Why These Tests Matter

What lymphoma-related labs can do

  • Provide baseline and context: blood counts, kidney/liver function, calcium, and LDH (a prognostic marker in many NHLs).

  • Help rule in/rule out look-alike conditions (infection, autoimmune disease).

  • Guide staging and risk scores (e.g., IPI for DLBCL, FLIPI for follicular lymphoma, MIPI for mantle cell, IPSfor Hodgkin).

  • Support treatment monitoring (e.g., trends in LDH, CBC, β2-microglobulin).

What they cannot do

  • Replace a biopsy—tissue (or core needle) biopsy with full hematopathology is essential to diagnose and subtypelymphoma.

  • Serve as universal “screening” tests for people without symptoms.


What These Tests Measure (at a glance)

General labs

  • CBC with differential: anemia, leukocytosis/leukopenia, thrombocytopenia.

  • Comprehensive metabolic panel (CMP): kidney/liver function, electrolytes; uric acid for tumor lysis risk.

  • LDH: cell-turnover marker; often correlates with tumor burden and goes into risk scores.

  • ESR/CRP: inflammatory activity (ESR frequently followed in HL).

  • β2-microglobulin: prognostic context for several NHLs; may reflect disease burden.

Infectious serologies (as directed by clinicians)

  • Hepatitis B & C, HIV (important before immunochemotherapy).

  • H. pylori testing when gastric MALT lymphoma is suspected.

Pathology & advanced diagnostics (performed on biopsy material)

  • Histopathology with immunohistochemistry (IHC): CD20, CD3, CD30, CD15, Ki-67, etc.

  • Flow cytometry (immunophenotyping): B-cell vs T-cell lineage, light-chain restriction.

  • Cytogenetics/FISH & molecular tests:

    • t(14;18)(BCL2) (follicular), BCL6MYC (DLBCL/Burkitt; “double/triple-hit” biology),

    • t(11;14)(CCND1) (mantle cell),

    • MYD88 L265P (Waldenström), T-cell receptor/IGH clonality assays.

Imaging (ordered by clinicians)

  • FDG-PET/CT (staging and response in most FDG-avid lymphomas; Deauville 5-point scale).

  • Contrast CT where PET is not indicated or to complement PET findings.


How the Testing Process Works

  1. Initial evaluation: your clinician orders CBC, CMP, LDH, ESR/CRP and reviews your history and exam.

  2. Definitive diagnosis: excisional or core needle biopsy of an involved node (or extranodal site) with full pathology, flow cytometry, IHC, FISH/molecular testing.

  3. Staging & baseline: PET/CT or CTviral serologies, ± β2-microglobulin; calculation of a risk score (e.g., IPI/FLIPI/MIPI/IPS).

  4. Monitoring: repeat CBC, CMP, LDH and disease-specific markers; imaging per guideline and clinician direction.


Interpreting Results (general guidance)

  • Elevated LDH, anemia, or abnormal counts support disease activity but are not diagnostic alone.

  • PET/CT defines stage and response (Deauville score).

  • Risk scores (IPI/FLIPI/MIPI/IPS) integrate age, stage, LDH, performance status, and other factors to estimate prognosis.

  • Viral serologies guide safe use of immunochemotherapy (e.g., hepatitis B reactivation risk).

All results must be interpreted with a hematology/oncology professional. A biopsy is required to diagnose and subtype lymphoma.


Choosing Panels vs. Individual Tests

  • First look (unexplained nodes/B symptoms): CBC, CMP, LDH, ESR/CRP with clinician exam; proceed to biopsy for diagnosis.

  • Before therapy: add hepatitis B/C and HIV screening; consider β2-microglobulin.

  • Subtype-specific workup (on biopsy): flow cytometryIHCFISH/molecular (e.g., BCL2/BCL6/MYCCCND1MYD88).

  • Monitoring: periodic CBC/CMP/LDH, and imaging when clinically indicated.


FAQs

Is there a screening blood test for lymphoma?
No. There is no routine screening. Evaluation starts with exam and basic labs, but a biopsy is required to confirm lymphoma.

Why do I need a biopsy if my labs are abnormal?
Because only tissue shows the cell type and genetic features that define the lymphoma subtype and guide treatment.

What does LDH tell me?
It’s a cell-turnover marker. Higher LDH often means more active disease and contributes to several risk scores.

What staging system is used?
Most lymphomas use Ann Arbor/Lugano staging with modern PET-CT; response is often graded with the Deauville 5-point scale.

Why test for hepatitis B/C or HIV?
These infections can affect treatment safety and choices—especially with anti-CD20 therapies—so clinicians check before therapy.


Internal Links & Cross-References

  • Cancer Screening Hub

  • Leukemia

  • Multiple Myeloma

  • Men’s Cancer & Tumor Markers

  • Women’s Cancer & Tumor Markers

  • Multi-Cancer Early Detection (MCED)

  • Key Lab Tests: CBC • CMP • LDH • β2-Microglobulin • ESR/CRP • Hepatitis B/C & HIV Panels • Lymphoma Flow Cytometry • Lymph Node Biopsy • FISH (BCL2/BCL6/MYC/CCND1) • MYD88 Mutation • PET/CT


References (no links)

  1. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014; updates referenced in subsequent consensus statements.

  2. National Comprehensive Cancer Network (NCCN). Guidelines for Patients: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Hodgkin Lymphoma. 2024–2025.

  3. American Cancer Society. Tests for Lymphoma (Hodgkin and Non-Hodgkin). Updated 2025.

  4. Barrington SF, Kluge R. FDG PET for therapy response assessment in lymphoma: Deauville 5-point scale and applications. Eur J Nucl Med Mol Imaging. 2016; practice updates through 2024.

  5. International Consensus/WHO/ICC updates on lymphoma classification and essential biomarkers (BCL2/BCL6/MYC, CCND1, MYD88). 2022–2024 summaries.

  6. Hepatitis B virus reactivation with anti-CD20 therapy: screening and prophylaxis recommendations summarized in hematology oncology guidelines (NCCN/ASCO). 2023–2025.


Available Tests & Panels

Tip: Begin with CBC, CMP, LDH and clinician exam. Biopsy with full hematopathology (flow/IHC/FISH/molecular) is required for diagnosis; labs and imaging support staging and monitoring.

  • Page
  • 1
  • of
  • 2
  • Total Rows
  • 30
Name Matches

The Complete Blood Count with Differential and Platelets Test is a comprehensive blood test that checks red blood cells, white blood cells, hemoglobin, hematocrit, and platelets. The differential analyzes types of white blood cells to detect infections, anemia, clotting abnormalities, immune conditions, and certain cancers. This essential test is often ordered for routine health exams, diagnosis, and monitoring treatment progress.

Blood
Blood Draw
Also Known As: CBC Test, CBC with Differential and Platelets Test, CBC w/Diff and Platelets Test, Full Blood Count Test, Complete Blood Count Test

Random
Phlebotomist

The Basic Metabolic Panel (BMP) Test measures eight markers, including glucose, calcium, sodium, potassium, chloride, carbon dioxide, BUN, and creatinine, to evaluate kidney function, blood sugar, and electrolyte balance. Doctors use this panel to detect diabetes, dehydration, and kidney disease, or to monitor treatment. It is commonly ordered in routine exams, emergency care, or pre-surgical testing to assess overall metabolic and organ health.

Blood
Blood Draw
Also Known As: BMP Test, Chemistry Panel, Chemistry Screen, Chem 7, Chem 11, SMA 7, SMAC7, Basic Metabolic Test, Chem Test, Chem Panel Test 

The Comprehensive Metabolic Panel (CMP) Test measures 21 markers to assess metabolic health, liver and kidney function, and electrolyte balance. It includes glucose, calcium, sodium, potassium, chloride, CO2, albumin, globulin, A/G ratio, total protein, bilirubin, ALP, AST, ALT, BUN, creatinine, BUN/creatinine ratio, and eGFR. The CMP helps detect diabetes, liver or kidney disease, and supports routine screening and chronic condition monitoring.

Blood
Blood Draw
Also Known As: CMP Test, Chemistry Panel Test, Chem Test, Chem 21 Test, Chem 14 Test 

The BUN Creatinine Ratio Test compares blood urea nitrogen (BUN) to creatinine levels to assess kidney function and hydration status. A high ratio may indicate dehydration, gastrointestinal bleeding, or high protein intake, while a low ratio can suggest liver disease or malnutrition. Doctors order this test with kidney panels to evaluate fatigue, swelling, or abnormal lab results. Results help diagnose renal issues and guide treatment planning.

Blood
Blood Draw
Also Known As: Blood Urea Nitrogen to Creatinine Ratio

Most Popular

The Creatinine Test measures creatinine levels in blood to evaluate kidney function and filtration efficiency. Elevated levels may indicate kidney disease, dehydration, or muscle disorders, while low levels may reflect reduced muscle mass. Doctors use this test to monitor chronic kidney disease (CKD), assess treatment response, and detect early signs of renal impairment. It provides key insight into kidney health, metabolic balance, and overall renal function.

Blood
Blood Draw
Also Known As: Blood Creatinine Test, Serum Creatinine Test

The Hepatic Function Panel Test measures liver enzymes, proteins, and bilirubin to assess liver health and function. It includes ALT, AST, ALP, albumin, total protein, and bilirubin levels. Abnormal results may indicate hepatitis, cirrhosis, fatty liver, or bile duct problems. Doctors use this test to investigate jaundice, nausea, abdominal pain, or fatigue and to monitor liver disease, alcohol use, or medication side effects affecting liver function.

Blood
Blood Draw
Also Known As: Liver Function Panel Test, LFT

The Liver Function Panel, also known as a Hepatic Function Panel, measures proteins, enzymes, and bilirubin to assess liver health and function. It helps detect liver disease, monitor liver conditions, and evaluate the effects of medications or other factors on liver performance.

Blood
Blood Draw
Also Known As: Hepatic Function Panel Test, HFP Test

The Hepatitis B Core Antibody Total Test with Reflex to IgM detects antibodies (anti-HBc) to the hepatitis B core antigen. If the total antibody test is reactive, reflex testing determines if IgM antibodies are present, which indicates recent or acute infection. A reactive total with non-reactive IgM suggests past or chronic infection. Doctors use this test to confirm exposure, distinguish acute from prior infection, and support hepatitis B screening and diagnosis.

Blood
Blood Draw

The Hepatitis B Immunity Panel Test evaluates immune status by measuring Hepatitis B surface antibody levels in the blood. A positive result typically indicates immunity from vaccination or past infection, while a negative result suggests susceptibility. This test is important for verifying protection, monitoring vaccine response, or determining if additional vaccination or further evaluation for Hepatitis B exposure is needed.


The Hepatitis B Surface Antibody Qualitative Test detects anti-HBs antibodies to the hepatitis B surface antigen and reports results as Reactive or Non-Reactive. A reactive result indicates past exposure, either from hepatitis B infection or prior vaccination, while a non-reactive result suggests no detectable exposure. Doctors use this test to confirm hepatitis B exposure history, evaluate vaccine response, and guide further preventive or diagnostic decisions.

Blood
Blood Draw
Also Known As: HBsAb Ql Test, Hep B Surface Ab Qualitative Test, HBs Ab Qual Test

The Hepatitis B Surface Antibody Quantitative Test measures the exact level of anti-HBs antibodies in blood to determine past exposure and whether protective immunity has developed from infection or vaccination. A higher antibody level generally indicates adequate immune response, while a low level suggests limited or no protection. Doctors use this test to confirm vaccine effectiveness, assess immune status, and support hepatitis B screening or preventive care.

Blood
Blood Draw
Also Known As: HBsAb Qn Test, Hepatitis B Titer Test

The Hepatitis B Surface Antigen (HBsAg) Test with Reflex to Confirmation screens for hepatitis B surface antigen in blood and, if reactive, automatically performs confirmatory testing. A reactive confirmed result indicates an active hepatitis B infection, while a non-reactive result shows no infection. Doctors use this test to diagnose acute or chronic hepatitis B, investigate abnormal liver tests, and guide treatment, monitoring, and infection control decisions.

Blood
Blood Draw
Also Known As: HBsAg Test, Hep B Surface Ag Test, HBs Antigen Test, Hep B Test

The Hepatitis C Antibody with HCV RNA Quantitative PCR test is a comprehensive diagnostic test used to detect and confirm the presence of the Hepatitis C virus (HCV) in the blood. It combines the initial screening for HCV antibodies with a quantitative polymerase chain reaction (PCR) test to measure the viral load.
Panel Contains Test:  Anti HCV Test, HCV Antibody Test, Hep C Antibody Test

The Hepatitis C Viral RNA Quantitative Test measures the amount of hepatitis C virus (HCV) RNA in blood to determine viral load. This test confirms active infection, evaluates disease severity, and monitors response to antiviral therapy. High viral load indicates significant viral replication, while lower or undetectable levels suggest effective treatment or controlled infection. Doctors use this test to guide therapy, track progress, and manage long-term liver health.

Also Known As: HCV RNA Test, Hepatitis C Viral Load Test, HCV PCR Test

The General Hepatitis Panel Test screens for multiple hepatitis infections in one order. It includes Hepatitis A Antibody Total, Hepatitis B Surface Antibody Qualitative, Hepatitis B Surface Antigen with Reflex to Confirmation, Hepatitis B Core Antibody Total, and Hepatitis C Antibody with Reflex to RNA PCR. Doctors use this panel to detect past exposure, confirm active or chronic infection, guide treatment, and support liver health monitoring.

Also Known As: Hepatitis Panel General

The C-Reactive Protein (CRP) Test measures CRP levels in blood to detect inflammation in the body. Elevated CRP may indicate infections, autoimmune disorders, or chronic diseases such as arthritis, cardiovascular disease, or inflammatory bowel disease. Doctors use this test to assess acute illness, monitor treatment response, and evaluate risk for heart disease. The CRP test provides key insight into inflammation, immune health, and overall wellness.

Blood
Blood Draw
Also Known As: CRP Test, Inflammation Test

The Direct Antiglobulin Test with Reflex to Anti C3 and Anti IgG evaluates immune-mediated red blood cell destruction by detecting antibodies or complement proteins. Abnormal findings may suggest autoimmune hemolytic anemia, drug-induced hemolysis, or transfusion reaction. Reflex testing helps distinguish complement activation from IgG involvement, offering insight into immune regulation and hematologic health.

Blood
Blood Draw
Also Known As: Direct Coombs Test, Coombs Direct Test, DAT Test

The Early Sjögren’s Syndrome Profile tests for antibodies to carbonic anhydrase VI (CA VI), salivary protein 1 (SP-1), and parotid specific protein (PSP) across IgG, IgA, and IgM isotypes. These novel biomarkers may appear before classic SS-A/SS-B antibodies, helping identify Sjögren’s syndrome earlier. This profile supports assessment of early autoimmune damage to salivary and lacrimal glands.

Blood
Blood Draw

The Electrolyte Panel Test measures sodium, potassium, chloride, and carbon dioxide in blood to evaluate fluid balance, kidney function, and acid-base status. Abnormal results may indicate dehydration, kidney disease, adrenal disorders, or respiratory issues. Doctors use this test to investigate symptoms such as weakness, confusion, or irregular heartbeat. Results provide essential insight into electrolyte balance, hydration, and overall metabolic and organ health.

Blood
Blood Draw
Also Known As: Lytes Panel, Anion Gap Panel, Electrolyte Test, Lytes Test, Anion Gap Test

Varied
Phlebotomist

The Galectin-3 Test measures levels of galectin-3, a biomarker linked to heart failure, cardiac fibrosis, and inflammation. Elevated results may indicate worsening heart disease, increased risk of hospitalization, or progression of chronic conditions. Doctors use this blood test to assess heart health, guide treatment decisions, and monitor patients with heart failure, offering valuable insight into long-term cardiovascular risk and management.

Blood
Blood Draw

The Total Immunoglobulins Panel measures IgA, IgG, and IgM levels to evaluate immune system function. Abnormal results may indicate immune deficiency, chronic infections, autoimmune disorders, or certain blood cancers. IgA helps protect mucous membranes, IgG provides long-term defense, and IgM is the body’s first response to infection. Doctors use this blood test to diagnose, monitor, and manage immune-related conditions and overall immune health.

Blood
Blood Draw

The Lactate Dehydrogenase (LDH) Test measures LDH enzyme levels in blood to assess tissue damage and overall health. Elevated LDH may indicate conditions such as liver disease, heart attack, anemia, infections, or certain cancers, while low levels are uncommon. Doctors use this test to help diagnose disease, monitor treatment effectiveness, and track cell damage. It provides valuable insight into metabolic activity and organ function.

Blood
Blood Draw
Also Known As: LD Test, LDH Test, Lactic Acid Dehydrogenase Test

Blood
Blood Draw

The localization of lymphocytes, a specific type of WBCs (or white blood cells), in one or more lymph nodes is what is referred to as lymphoma – a cancer.  In both the lymphatic and blood circulatory systems, lymphocytes travel all over the body.  Tissue fluids are drained and carried all over the body as lymph and then back to the blood circulatory system via the lymphatic system, which is a network of lymph nodes and vessels (or lymphatics).  In areas such as the groin, neck, chest, armpits, and abdomen, lymph nodes are found in chains or individually. As the lymph fluid goes through the nodes (tiny lymphoid tissue organs whose job it is to filter lymph), abnormal cells and microorganisms are destroyed. Natural killer cells, T-lymphocytes and B-lymphocytes are some of the lymphocytes and macrophages contained in lymph nodes.         

The immune system is controlled by T-lymphocytes.  When it comes to immune responses, these lymphocytes decide when a response is necessary, its scale or severity, in addition to triggering it.  Furthermore, they counteract a variety of foreign bodies attacking the body.  B-lymphocytes work to create antibodies that are activated when an individual gets a vaccine against hepatitis, mumps or measles, or any other diseases. 10 to 15 percent of all the lymphocytes in the bloodstream are of the natural killer (or NK) variety, another type of lymphocytes.  Abnormal cells that have been attacked by viruses and cancerous cells are usually attacked and killed by NK cells.    

In the case of lymphoma, any of these cells may be involved either singly or as a combination.  The occurrence of abnormal cells in the lymph nodes, one or more, or lymphoid tissues could signal the onset of lymphoma.  The uncontrollable reproduction of these cells means that their number exceeds that of normal cells in the affected node causing the node to grow in size before the abnormal cells start spreading to other nodes in the lymphatic system.  The abnormal cells may also travel to the tonsils, thymus, bone marrow, adenoids and spleen, and other organs closely related to the lymphatic system.     

T-cell lymphomas are less common than B-cell lymphomas.  

Symptoms of Lymphoma  

The lymph nodes in the groin, neck, and armpits may swell painlessly and/or the spleen becomes enlarged in people with lymphoma.  Increased levels of abnormal lymphocytes may also be discovered in the blood of affected individuals.  Additional signs and symptoms of lymphoma include:    

  • Episodes of chills and fever 
  • Fatigue 
  • Instances of night sweats  
  • Significant loss of weight, up to 10 percent or higher, for no apparent reason  
  • Diminished appetite 
  • Pain in the neck or flank 
  • Itchiness  

The individual’s breathing may be affected if the lymph node in question is located in the chest area.  If the affected lymph node is in the abdomen, abdominal pain may be experienced.  Since the above symptoms may be mild in nature, diagnosing lymphoma may, at times, be quite hard.  While some people may experience a low-grade fever, others may not have any noticeable signs.  The physician, or individual suffering from lymphoma, may not be able to feel or see the swollen lymph node even though it is there.   

Hodgkin Disease/Lymphoma   

The presence of Reed-Sternberg cells, big unique cells, characterizes Hodgkin disease/lymphoma.  

People between the ages of twenty and forty years, as well as those over the age of 55, have a higher prevalence of Hodgkin lymphoma.  Each year, around 9,000 individuals in the US are diagnosed with this disease, with 1,300 deaths, according to the ACS (or American Cancer Society).    

A variety of theories have attempted to explain the cause of Hodgkin Lymphoma.  The involvement of a virus, or other infectious agent, has been mentioned in a number of them.  According to other theories, cell mutations are to blame.  Specific causes are yet to be identified, even though research is still ongoing.  Similarly, there has been no clear explanation as to why males appear to be more vulnerable to HL.    

Based on the cells that are present as well as the abnormal lymph node structure, Hodgkin Lymphoma can be further divided.  A depletion of lymphocytes, a higher number of small lymphocytes, or a combination of various types of cells or fibrosis (occurrence of bands of scarring) may be seen in lymph nodes.  With HL,  a benign, mostly mixed, reactive cell population forms the majority of the cells in the lymph nodes, while Reed-Sternberg cells (tumor cells) are the minority.                                      

Non-Hodgkin Lymphoma  

About 4 percent of all newly diagnosed cancer cases in the US are Non-Hodgkin lymphoma.  This lymphoma is slightly more common in Caucasians and men than in women.  Individuals with a compromised immune system, those with HIV/AIDS, as well as those at an advanced age, face a higher risk of developing this disease.   

While around 20,000 people die from the disease annually, around 72,000 are diagnosed in a similar period according to the American Cancer Society.  Since the 1970s, the occurrence of the disease is almost double.  While cases relating to women account for the highest increase, the main reason for the upward trend is yet to be discovered.  Since the late nineties, however, non-Hodgkin lymphoma related deaths have been on the decrease.    

The systems used to classify the many different types of non-Hodgkin lymphoma have evolved as understanding about them grows.  Some of the changes in the classification systems used are attributed to the introduction of new methods of evaluating the cells involved in the disease.   

Many doctors have adopted the REAL (or Revised European American Lymphoma) classification proposed by the International Lymphoma Study Group back in the nineties.  The main function that the cell should be providing was the main focus of this classification.  For instance, while cell to cell interactions are left to T-lymphocytes, the main function of B-lymphocytes is to produce antibodies.  These characteristics are combined with genetic and phenotypic studies of the cells under the WHO (or World Health Organization) classification system – which is also the latest system.  Having been adopted by many healthcare professionals as the current standard, the World Health Organization classification added to the REAL classification.    

Non-Hodgkin Lymphoma Types  

Due to the various classification systems and changes made to them over the years, non-Hodgkin lymphoma classification can be somewhat confusing.  Natural Killer and T- cell lymphomas are less common in the US than B-cell non-Hodgkin lymphomas.  Around 15 percent of non-Hodgkin lymphomas affect T-lymphocytes, with approximately 85 percent involving mature B-lymphocytes.  

The following are some of the most common B-cell lymphomas types:   

* DLBCL (or Diffuse Large B-cell Lymphoma).  Of all non-Hodgkin lymphoma cases in the US, DLBCL constitutes about a third. While this disease mostly occurs in older individuals, it can affect anyone and is considered to grow swiftly.  

* Follicular Lymphoma.  About a fifth of all lymphoma cases in the US are of this type.  Over time, about a third of all Follicular lymphomas turn into the fast-growing DLBCL type described above, even though they are generally known to grow slower.  

* B-cell chronic lymphocytic lymphoma / small lymphocytic lymphoma (or CLL/ SLL).  

Characterized by small lymphoma cells, CLL/SLL is a slowly progressing disease.  The lymphoma cells are mostly small-sized.  While SLL generally involves the lymph nodes, CLL is predominantly found in the bone marrow; however, both of these are considered the same disease and combined make up about 24 percent of all lymphomas.   

The following are some of the main types of T-cell lymphomas:  

* Precursor T-lymphoblastic lymphoma (leukemia). Depending on where the affected cells are located, in the bone marrow or the blood, this disease can be considered to be leukemia or lymphoma.  Of all lymphoma cases, about 1 percent fall under this category.   

* Peripheral or Mature T-cell lymphomas.  4 to 5 percent of all lymphomas fall under the different known categories of mature T-cell lymphomas.    

* Sezary Syndrome, Mycosis Fungoides, and Other Types Of Cutaneous T-Cell Lymphomas.  These types of lymphomas are different from other types because, unlike the rest, they start on the skin instead of internal organs or lymphoid tissue.  This means that even though they are quite uncommon, they very unique.  Of all non-melanoma skin cancer cases, this specific group makes up less than 1 percent. Five percent of all lymphomas are skin lymphomas.  

Lymphoma Testing  

When it comes to testing, the main goal is to distinguish the condition from other conditions and recognize and keep track of complications, if any, in addition to diagnosing and staging the lymphoma.  To diagnose lymphoma a few blood tests can be used.  

Lab Testing  

The examination of affected lymphoid tissue and lymph nodes by a pathology specialist is the gold standard when it comes to testing for both non-Hodgkin and Hodgkin lymphomas.  Using a fine needle aspiration procedure or biopsy obtained from the affected lymph tissue or node, the sample is evaluated microscopically.     

The following lab tests may also be used:  

CBC (or Complete Blood Count).  To rule out leukemia and other non-lymphoma conditions and to test for the presence of anemia, a CBC may be administered.  The CBC can identify low platelet or low white blood cell counts that may indicate whether lymphoma is present in the blood and/or bone marrow   

* Biopsy and Evaluation of The Bone Marrow.  The cells in the bone marrow are examined using this test.  Lymphoid aggregates and/or abnormal lymphoid cells may be found with lymphoma.  

* Immunophenotyping.  By testing for specific identifying markers inside or on the membrane of cells, this test can be used to spot affected cells.  Usually listed numerically, these commonly used identifying factors are referred to as CD (or clusters of differentiation).  Classification of the cells is possible by creating a list of the clusters of differentiation present on the cells.  Immunohistochemistry and flow cytometry are a couple of the ways in which this test can be conducted.   

* Chromosome Analysis Test.  To establish whether bits of chromosomes have moved, chromosome analysis evaluates the chromosomes in the cancer cell nucleus. For lymphomas, this test is rarely used.   

* Molecular Genetic Analysis Tests.  To establish whether the cells under consideration belong to one clone, molecular genetic analysis can be used to look for genetic changes by examining the DNA of the cancerous cell.  

* Body fluids, including cerebrospinal fluid, can be analyzed if the lymphoma is thought to have spread to other parts of the body.  

Beta-2 Microglobulin Test.  The prognosis may be predicted with the help of the Beta-2 Microglobulin test.  

Serum Creatinine Test.  If a disease referred to as nephritic syndrome, affecting the kidneys, is linked with Hodgkin lymphoma, serum creatinine levels may be higher than normal.  

* Studies of Serum Chemistry.  The prognosis may also be determined with the help of serum chemistry studies such as LDH (or lactate dehydrogenase).  

Hepatitis B Test.  * Since rituximab therapy is linked with negative side effects in individuals suffering from hepatitis B, a hepatitis B test is used to determine the suitability of the treatment.  

* HIV (Human Immunodeficiency Virus) Test.  The lymphoma outcome in HIV patients may be improved by using an antiretroviral treatment. 

Non-laboratory Tests. 

The following non-laboratory tests may be used primarily to help stage and monitor lymphoma: 

* MRI (or magnetic resonance imaging). 

* Exploratory surgery (only necessary on occasion). 

* Physical examination. 

* CT (or computed tomography) scans. 

* PET (or positron emission tomography) scans. 

* Chest X-ray.